Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival

New preclinical and translational findings position DNase I as a potentially transformative adjunct therapy for CAR-T treatment in aggressive B cell malignancies Data highlight potential of DNase I to improve CAR-T cell expansion, reduce exhaustion and enhance tumor control across hematologic cancer models Findings support continued clinical development of DNase I as a combinatorial strategy to augment CAR-T cell therapies in difficult-to-treat cancers Data to be presented today as a poster presentation at the ASCO 2026 annual meeting FRAMINGHAM, MA / ACCESS Newswire / June 1, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced positive preclinical data will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting demonstrating that DNase I significantly enhances CAR-T cell expansion, persistence, and antitumor efficacy in aggressive hematologic cancer models. Presentation Details: Session Title: Hematologic Malignancies - Plasma Cell Dyscrasia (Poster Session) Abstract Title: Targeting cfDNA and NETs with DNase I to augment CAR-T cell function and antitumor efficacy Poster Board: 410 Presentation Date & Time: June 1, 2026, 9:00 AM - 12:00 PM CDT Presenter: Alexey V.